{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Human+Activity+Profile",
    "query": {
      "intervention": "Human Activity Profile"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 19,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Human+Activity+Profile&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-07T03:38:14.957Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03388632",
      "title": "Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Tumors",
        "Treatment-Refractory Cancers"
      ],
      "interventions": [
        {
          "name": "rhIL-15",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Tumor biopsies",
          "type": "PROCEDURE"
        },
        {
          "name": "EKG",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "ECHO",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "CT Scan",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 31,
      "start_date": "2018-02-05",
      "completion_date": "2025-05-08",
      "has_results": true,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-09-07T03:38:14.957Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03388632"
    },
    {
      "nct_id": "NCT04827810",
      "title": "A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Gamitrinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2021-11-05",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-29",
      "last_synced_at": "2026-09-07T03:38:14.957Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04827810"
    },
    {
      "nct_id": "NCT02034123",
      "title": "Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Small Cell"
      ],
      "interventions": [
        {
          "name": "GSK2879552",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2014-02-04",
      "completion_date": "2017-04-18",
      "has_results": true,
      "last_update_posted_date": "2019-12-06",
      "last_synced_at": "2026-09-07T03:38:14.957Z",
      "location_count": 3,
      "location_summary": "St Louis, Missouri • Columbus, Ohio • Nashville, Tennessee",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02034123"
    },
    {
      "nct_id": "NCT03724747",
      "title": "Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer (mCRPC)"
      ],
      "interventions": [
        {
          "name": "BAY2315497 Injection",
          "type": "DRUG"
        },
        {
          "name": "Darolutamide(BAY1841788)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 63,
      "start_date": "2018-12-18",
      "completion_date": "2024-10-31",
      "has_results": false,
      "last_update_posted_date": "2024-11-08",
      "last_synced_at": "2026-09-07T03:38:14.957Z",
      "location_count": 3,
      "location_summary": "New Orleans, Louisiana • Omaha, Nebraska • New York, New York",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03724747"
    },
    {
      "nct_id": "NCT03981978",
      "title": "Validity of Physical Activity Questionnaires in Persons Pursuing Bariatric Surgery",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bariatric Surgery Candidate",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Physical Activity",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2020-01-01",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-09-29",
      "last_synced_at": "2026-09-07T03:38:14.957Z",
      "location_count": 2,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03981978"
    },
    {
      "nct_id": "NCT06781723",
      "title": "Improving the Anabolic Action of Plant-based Foods Using Complementary Proteins",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Health",
        "Recreational Activities",
        "Muscle Protein Synthetic Response to Protein",
        "Muscle Protein Synthesis"
      ],
      "interventions": [
        {
          "name": "Resistance Exercise",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Isolated Mixture",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Rice and Beans",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "University of Illinois at Urbana-Champaign",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "20 Years to 35 Years"
      },
      "enrollment_count": 11,
      "start_date": "2024-09-05",
      "completion_date": "2025-04-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-08",
      "last_synced_at": "2026-09-07T03:38:14.957Z",
      "location_count": 1,
      "location_summary": "Urbana, Illinois",
      "locations": [
        {
          "city": "Urbana",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06781723"
    },
    {
      "nct_id": "NCT04338685",
      "title": "A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Hepatocellular",
        "Biliary Tract Cancer",
        "Secondary Liver Cancer",
        "Liver Metastases"
      ],
      "interventions": [
        {
          "name": "RO7119929",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2020-07-16",
      "completion_date": "2023-01-09",
      "has_results": true,
      "last_update_posted_date": "2024-12-09",
      "last_synced_at": "2026-09-07T03:38:14.957Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04338685"
    },
    {
      "nct_id": "NCT02167607",
      "title": "A Pilot Study to Characterize the Bioavailability and Plasma Profile of Potato Polyphenols in Humans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Premenopausal Women",
        "Overweight and Obese Women"
      ],
      "interventions": [
        {
          "name": "Active Comparator",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo Comparator",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Clinical Nutrition Research Center, Illinois Institute of Technology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "20 Years to 45 Years · Female only"
      },
      "enrollment_count": 13,
      "start_date": "2014-06-01",
      "completion_date": "2014-11-11",
      "has_results": false,
      "last_update_posted_date": "2021-01-28",
      "last_synced_at": "2026-09-07T03:38:14.957Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02167607"
    },
    {
      "nct_id": "NCT00720304",
      "title": "Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "fluorescence in situ hybridization",
          "type": "GENETIC"
        },
        {
          "name": "polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "immunoenzyme technique",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "intensity-modulated radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC",
        "OTHER",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2007-11-19",
      "completion_date": "2015-11-13",
      "has_results": true,
      "last_update_posted_date": "2024-08-22",
      "last_synced_at": "2026-09-07T03:38:14.957Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00720304"
    },
    {
      "nct_id": "NCT06333496",
      "title": "Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Blood Sugar; High",
        "Overweight and Obesity",
        "Fat Burn",
        "Obesity",
        "Heart Health Markers"
      ],
      "interventions": [
        {
          "name": "GLP-1 Booster (GB)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Alpine Biotech LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2024-01-02",
      "completion_date": "2024-05-08",
      "has_results": false,
      "last_update_posted_date": "2024-12-05",
      "last_synced_at": "2026-09-07T03:38:14.957Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06333496"
    }
  ]
}